Orexin Receptor Type 2 - Drugs In Development, 2021
Orexin Receptor Type 2 - Drugs In Development, 2021
SUMMARY
According to the recently published report 'Orexin Receptor Type 2 - Drugs In Development, 2021'; Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) pipeline Target constitutes close to 16 molecules. Out of which approximately 15 molecules are developed by companies and remaining by the universities/institutes.
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Orexin receptor type 2 (Ox2R or OX2) also known as hypocretin receptor type 2, is a protein that is encoded by the HCRTR2 gene. OX2 is a G-protein coupled receptor expressed exclusively in the brain. OX2 binds both orexin A and orexin B neuropeptides. OX2 is involved in the central feedback mechanism that regulates feeding behavior.
The report 'Orexin Receptor Type 2 - Drugs In Development, 2021' outlays comprehensive information on the Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 4, 2, 3 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Respiratory, Gastrointestinal and Toxicology which include indications Narcolepsy, Insomnia, Obstructive Sleep Apnea, Chronic Obstructive Pulmonary Disease (COPD), Delirium, Dementia, Dementia Associated With Alzheimer's Disease, Hypersomnia, Major Depressive Disorder, Mild Cognitive Impairment, Neurology, Opioid Induced Side Effects, Parkinson's Disease, Reflux Esophagitis (Gastroesophageal Reflux Disease), Sleep Disorders and Unspecified Neurologic Disorders.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
According to the recently published report 'Orexin Receptor Type 2 - Drugs In Development, 2021'; Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) pipeline Target constitutes close to 16 molecules. Out of which approximately 15 molecules are developed by companies and remaining by the universities/institutes.
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Orexin receptor type 2 (Ox2R or OX2) also known as hypocretin receptor type 2, is a protein that is encoded by the HCRTR2 gene. OX2 is a G-protein coupled receptor expressed exclusively in the brain. OX2 binds both orexin A and orexin B neuropeptides. OX2 is involved in the central feedback mechanism that regulates feeding behavior.
The report 'Orexin Receptor Type 2 - Drugs In Development, 2021' outlays comprehensive information on the Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 4, 2, 3 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Respiratory, Gastrointestinal and Toxicology which include indications Narcolepsy, Insomnia, Obstructive Sleep Apnea, Chronic Obstructive Pulmonary Disease (COPD), Delirium, Dementia, Dementia Associated With Alzheimer's Disease, Hypersomnia, Major Depressive Disorder, Mild Cognitive Impairment, Neurology, Opioid Induced Side Effects, Parkinson's Disease, Reflux Esophagitis (Gastroesophageal Reflux Disease), Sleep Disorders and Unspecified Neurologic Disorders.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2)
- The report reviews Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Overview
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Companies Involved in Therapeutics Development
Centessa Pharmaceuticals Plc
Eisai Co Ltd
Idorsia Pharmaceutical Ltd
Inexia Ltd
Johnson & Johnson
Merck & Co Inc
NLS Pharma Group
Synchronicity Pharma Inc
Taisho Pharmaceutical Holdings Co Ltd
Takeda Pharmaceutical Co Ltd
Yangtze River Pharmaceutical Group
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Drug Profiles
daridorexant hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lemborexant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mazindol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OPN-021 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides to Agonize Orexin 2 Receptor for Narcolepsy and Unspecified Neurologic Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
seltorexant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize Orexin-2 for Narcolepsy and Sleep Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize Orexin Receptor for Narcolepsy and Sleep Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize Orexin-2 for Narcolepsy and Neurological Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
suvorexant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-861 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-925 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-994 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TS-142 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YNT-185 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YZJ-1139 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Dormant Products
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Discontinued Products
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Product Development Milestones
Featured News & Press Releases
Jun 30, 2021: Eisai launches in-house developed anti-insomnia drug Dayvigo (Lemborexant) in Hong Kong
Jun 09, 2021: Idorsia to present new Phase 3 data on daridorexant in insomnia at SLEEP 2021
Jun 09, 2021: Eisai to present latest data of Lemborexant at 35th Annual Sleep Meeting
May 18, 2021: NLS Pharmaceutics announces new study data confirming Mazindol's unique orexin pathway activation for treating narcolepsy
Mar 29, 2021: NLS Pharmaceutics announces issuance of Canadian Patent covering its novel formulation of controlled-release Mazindol (Mazindol CR)
Mar 10, 2021: FDA accepts the new drug application for review of Idorsia’s daridorexant for the treatment of adult patients with insomnia
Mar 03, 2021: Idorsia submits European marketing authorisation application for daridorexant for the treatment of adult patients with insomnia
Mar 02, 2021: New Drug Approval for in-house developed anti-insomnia drug Dayvigo (Lemborexant) in Hong Kong
Feb 04, 2021: Health Canada authorizes DAYVIGO (lemborexant)
Nov 02, 2020: Eisai to present on lemborexant at Digital CTAD 2020
Oct 28, 2020: Eisai to present on lemborexant at 13th Clinical Trials on Alzheimer’s Disease (CTAD) conference
Aug 28, 2020: Eisai presents new analyses from phase 3 studies of DAYVIGO (lemborexant) CIV for the treatment of insomnia in adult patients at Virtual SLEEP 2020
Aug 28, 2020: Daridorexant Phase 3 results in insomnia presented at SLEEP 2020
Aug 25, 2020: Eisai to present latest data of lemborexant at 34th Annual Sleep Meeting (SLEEP 2020)
Aug 13, 2020: Daridorexant Phase 3 results in insomnia to be presented at SLEEP 2020
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Overview
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Companies Involved in Therapeutics Development
Centessa Pharmaceuticals Plc
Eisai Co Ltd
Idorsia Pharmaceutical Ltd
Inexia Ltd
Johnson & Johnson
Merck & Co Inc
NLS Pharma Group
Synchronicity Pharma Inc
Taisho Pharmaceutical Holdings Co Ltd
Takeda Pharmaceutical Co Ltd
Yangtze River Pharmaceutical Group
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Drug Profiles
daridorexant hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lemborexant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mazindol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OPN-021 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides to Agonize Orexin 2 Receptor for Narcolepsy and Unspecified Neurologic Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
seltorexant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize Orexin-2 for Narcolepsy and Sleep Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize Orexin Receptor for Narcolepsy and Sleep Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize Orexin-2 for Narcolepsy and Neurological Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
suvorexant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-861 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-925 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-994 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TS-142 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YNT-185 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YZJ-1139 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Dormant Products
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Discontinued Products
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Product Development Milestones
Featured News & Press Releases
Jun 30, 2021: Eisai launches in-house developed anti-insomnia drug Dayvigo (Lemborexant) in Hong Kong
Jun 09, 2021: Idorsia to present new Phase 3 data on daridorexant in insomnia at SLEEP 2021
Jun 09, 2021: Eisai to present latest data of Lemborexant at 35th Annual Sleep Meeting
May 18, 2021: NLS Pharmaceutics announces new study data confirming Mazindol's unique orexin pathway activation for treating narcolepsy
Mar 29, 2021: NLS Pharmaceutics announces issuance of Canadian Patent covering its novel formulation of controlled-release Mazindol (Mazindol CR)
Mar 10, 2021: FDA accepts the new drug application for review of Idorsia’s daridorexant for the treatment of adult patients with insomnia
Mar 03, 2021: Idorsia submits European marketing authorisation application for daridorexant for the treatment of adult patients with insomnia
Mar 02, 2021: New Drug Approval for in-house developed anti-insomnia drug Dayvigo (Lemborexant) in Hong Kong
Feb 04, 2021: Health Canada authorizes DAYVIGO (lemborexant)
Nov 02, 2020: Eisai to present on lemborexant at Digital CTAD 2020
Oct 28, 2020: Eisai to present on lemborexant at 13th Clinical Trials on Alzheimer’s Disease (CTAD) conference
Aug 28, 2020: Eisai presents new analyses from phase 3 studies of DAYVIGO (lemborexant) CIV for the treatment of insomnia in adult patients at Virtual SLEEP 2020
Aug 28, 2020: Daridorexant Phase 3 results in insomnia presented at SLEEP 2020
Aug 25, 2020: Eisai to present latest data of lemborexant at 34th Annual Sleep Meeting (SLEEP 2020)
Aug 13, 2020: Daridorexant Phase 3 results in insomnia to be presented at SLEEP 2020
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indication, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021 (Contd..2)
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by Centessa Pharmaceuticals Plc, 2021
Pipeline by Eisai Co Ltd, 2021
Pipeline by Idorsia Pharmaceutical Ltd, 2021
Pipeline by Inexia Ltd, 2021
Pipeline by Johnson & Johnson, 2021
Pipeline by Merck & Co Inc, 2021
Pipeline by NLS Pharma Group, 2021
Pipeline by Synchronicity Pharma Inc, 2021
Pipeline by Taisho Pharmaceutical Holdings Co Ltd, 2021
Pipeline by Takeda Pharmaceutical Co Ltd, 2021
Pipeline by Yangtze River Pharmaceutical Group, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Discontinued Products, 2021
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indication, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021 (Contd..2)
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by Centessa Pharmaceuticals Plc, 2021
Pipeline by Eisai Co Ltd, 2021
Pipeline by Idorsia Pharmaceutical Ltd, 2021
Pipeline by Inexia Ltd, 2021
Pipeline by Johnson & Johnson, 2021
Pipeline by Merck & Co Inc, 2021
Pipeline by NLS Pharma Group, 2021
Pipeline by Synchronicity Pharma Inc, 2021
Pipeline by Taisho Pharmaceutical Holdings Co Ltd, 2021
Pipeline by Takeda Pharmaceutical Co Ltd, 2021
Pipeline by Yangtze River Pharmaceutical Group, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Discontinued Products, 2021
LIST OF FIGURES
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021
